Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Hemostemix Inc. (V:HEM)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
Company Contact
Address: Suite 730; 1015 - 4 St SW
Tel: N/A
IR: See website
Key People
Thomas A. Smeenk
President, Chief Executive Officer, Director
Christina Wu
Interim Chief Financial Officer
Business Overview
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient's blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
Financial Overview
For the fiscal year ended 31 December 2023, Hemostemix Inc revenues was not reported. Net loss decreased 52% to C$2.5M. Lower net loss reflects Professional fees decrease of 88% to C$269K (expense), Research and development decrease of 38% to C$385K (expense), Office rent and office maintenance decrease of 18% to C$375K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.07 to -C$0.03.
Reporting Currency: Canadian Dollars
Enterprise value: $7.66M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$2.15M as of Dec 31, 2023
Net annual income (TTM): -$2.50M as of Dec 31, 2023
Free cash flow (TTM): -$1.42M as of Dec 31, 2023
Net Debt Last Fiscal Year: $4.17M as of Dec 31, 2023
Shares outstanding: 87,122,318 as of Dec 31, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization